
Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) – Research analysts at HC Wainwright increased their FY2026 earnings per share estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($2.50) per share for the year, up from their previous forecast of ($2.82). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q4 2026 earnings at ($0.57) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.69) EPS, FY2027 earnings at ($2.70) EPS, FY2028 earnings at ($3.39) EPS, FY2029 earnings at ($3.46) EPS and FY2030 earnings at ($3.02) EPS.
ANRO has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. BTIG Research reissued a “buy” rating and set a $37.00 price target on shares of Alto Neuroscience in a report on Wednesday, November 11th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Finally, Wedbush upped their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.88.
View Our Latest Research Report on Alto Neuroscience
Alto Neuroscience Trading Down 8.4%
Shares of NYSE:ANRO opened at $27.06 on Monday. Alto Neuroscience has a 52 week low of $12.51 and a 52 week high of $37.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.85 and a current ratio of 18.12. The company’s fifty day moving average is $26.21 and its 200-day moving average is $24.69.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.13.
Insider Transactions at Alto Neuroscience
In other Alto Neuroscience news, CFO Nicholas Smith sold 110,830 shares of Alto Neuroscience stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total value of $2,945,861.40. Following the completion of the transaction, the chief financial officer owned 24,060 shares in the company, valued at approximately $639,514.80. The trade was a 82.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 11.25% of the company’s stock.
Institutional Trading of Alto Neuroscience
Several large investors have recently made changes to their positions in ANRO. Sterling Capital Management LLC increased its stake in shares of Alto Neuroscience by 1,045.7% in the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock valued at $27,000 after buying an additional 962 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Alto Neuroscience by 48,581.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock worth $137,000 after buying an additional 5,344 shares in the last quarter. GK Wealth Management LLC acquired a new position in Alto Neuroscience during the 2nd quarter worth about $226,000. Empowered Funds LLC acquired a new position in Alto Neuroscience during the 3rd quarter worth about $299,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Alto Neuroscience during the 1st quarter worth about $534,000.
Top Alto Neuroscience Stories
These are some of the ANRO stories that stood out recently:
- Positive Sentiment: Zacks upgraded ANRO to Rank #2 (Buy), citing improving optimism about the company’s earnings prospects. Article: Alto Neuroscience upgraded to Buy
- Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, projecting smaller losses than before for multiple periods, while maintaining a Buy rating. Its FY2026 loss estimate now matches the $2.50-per-share consensus. Article: HC Wainwright estimate revisions
- Positive Sentiment: Analysts’ average price target is reported at $37.88, implying roughly 29% potential upside from the reference price. Price targets are estimates and may not reliably predict returns. Article: Analyst price target and potential upside
Alto Neuroscience Company Profile
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
